Standard BioTools Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1M | $21.1M | $23.8M | $19.6M | $21.8M | $20.2M | $890.0K | $22.1M |
| Cost of Revenue | $9.6M | $9.8M | $12.4M | $10.1M | $11.1M | $9.2M | $2.7M | $10.0M |
| Gross Profit | $10.5M | $11.3M | $11.4M | $9.5M | $10.6M | $11.0M | $-1.8M | $12.1M |
| Gross Margin | 52.4% | 53.5% | 47.8% | 48.5% | 48.8% | 54.6% | -202.8% | 54.9% |
| Operating Expenses | ||||||||
| Research & Development | $2.0M | $2.1M | $8.0M | $6.4M | $6.2M | $5.4M | $-1.3M | $6.9M |
| SG&A Expense | $16.4M | $18.6M | $25.3M | $26.6M | $28.1M | $29.8M | $6.8M | $24.5M |
| Operating Income | $-25.4M | $-12.5M | $-24.6M | $-32.9M | $-25.7M | $-27.0M | $-10.3M | $-26.7M |
| Operating Margin | -126.3% | -59.1% | -103.6% | -168.5% | -118.1% | -133.4% | -1,162.1% | -120.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-21.4M | $-14.6M | $-22.0M | $-32.9M | $-18.3M | $-23.5M | $-11.2M | $-21.8M |
| Income Tax Expense | $90.0K | $11.0K | $-35.9M | $-1.2M | $-609.0K | $-119.0K | $257.0K | $118.0K |
| Net Income | $-26.8M | $127.1M | $19.3M | $-34.7M | $-33.5M | $-26.0M | $-34.1M | $-26.9M |
| Net Margin | -133.1% | 600.9% | 81.0% | -177.4% | -153.7% | -128.7% | -3,828.3% | -122.0% |
| EPS (Basic) | $-0.07 | $0.33 | $0.05 | $-0.02 | $-0.09 | $-0.07 | $-0.06 | $-0.02 |
| EPS (Diluted) | $-0.07 | $0.33 | $0.05 | $-0.02 | $-0.09 | $-0.07 | $-0.06 | $-0.02 |
| Shares Outstanding (Basic) | 390.9M | 388.2M | 381.6M | 1.53B | 380.5M | 378.2M | 353.2M | 1.49B |
| Shares Outstanding (Diluted) | 390.9M | 388.2M | 381.6M | 1.53B | 380.5M | 378.2M | 353.2M | 1.49B |
| Dividends Per Share | — | — | — | — | — | — | — | — |